Biosimilars Medical Academy Steering Committee
Dr. Maria Cuadrado
Guy's and St Thomas' Hospital, London, United Kingdom
After graduating from Malaga University, Spain, with a degree in medicine in 1979, Dr. Maria Cuadrado was awarded a PhD from Córdoba University in 1990. After working as a Louise Coote Research Fellow as part of the largest lupus unit in Europe, Dr. Cuadrado became a consultant rheumatologist at Guy's and St. Thomas', London, UK, in 2003. She was also senior lecturer of King's College London. Since February 2018, she is Head of Rheumatology Department at Clinica Universidad de Navarra-Madrid and Professor of Rheumatology at the Universidad de Navarra.
Dr. Cuadrado's specialist clinical interest is in pathogenic mechanisms and treatment of systemic autoimmune diseases, and she has published more than 100 papers in peer-reviewed journals. She is co-editor of several books on systemic lupus erythematosus and has published numerous book chapters on several systemic autoimmune disease areas.
She is also regular speaker at international meetings on inflammatory diseases in rheumatology and has been a co-organizer of the prestigious meeting, 'Ten Topics in Rheumatology', held annually in Barcelona since 2006.
Dr. Cuadrado has a long been interested in the field of biosimilars, publishing her first paper on this subject in 2008.
Maria Cuadrado has no disclosures.
Prof. Maurizio Cutolo
Director of Research Laboratories and Clinical Academic
Unit of Rheumatology, University of Genova, Genova, Italy
Prof. Maurizio Cutolo is Professor of Rheumatology and Professor of Internal Medicine, Director of Research Laboratories, Academic Division of Clinical Rheumatology and Postgraduate School of Rheumatology, University of Genova, Italy.
As former President of both the European League Against Rheumatism (EULAR) (2013–2015) and the International League (ILAR), Prof. Cutolo has also served as Chairman of the Committee for Education and Training of EULAR and Chairman of Associations for Rheumatology (ILAR), and is both a board member and former Vice President of the International Society for NeuroImmunoModulation (ISNIM), and former Vice President of the Italian Society for Rheumatology.
Prof. Cutolo is a co-founder and former Chairman of two study groups at the American College of Rheumatology (ACR): that on NeuroEndocrine Immunology of the Rheumatic Diseases and that on Capillaroscopy and Rheumatic Diseases, and is the founder and Chairman of the study group on Neuroimmune Endocrinology at EULAR. He is also a member of the Editorial Board of Annals of the Rheumatic Diseases and Current Opinion in Rheumatology, and Associate Editor of Clinical and Experimental Rheumatology.
Prof. Cutolo is also heavily involved in both pre-clinical and clinical research into advanced therapies in systemic sclerosis; capillaroscopy in rheumatic diseases; role of sex hormones in the immune response and rheumatic diseases; the endocrine system of vitamin D; the chronotherapy of rheumatoid arthritis with night glucocorticoids; synovial macrophages as targets for biologicals in rheumatoid arthritis; chronic inflammation and cancer; and the role of biosimilars in rheumatic diseases.
Maurizio Cutolo has received funds for research from: Actelion, BMS, Celgene, Boehringer Ingelheim, Mundipharma, and Horizon.
Prof. Tore K. Kvien
Department of Rheumatology, Diakonhjemmet
Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo
Prof. Tore K. Kvien has been Professor of Rheumatology at the University of Oslo, Norway, since 1997 and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo from 1994 to 2019. His current major research activities include epidemiological and health service research, with a focus on frequently occurring diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Special focus is also directed on complications of rheumatic diseases, for example osteoporosis and cardiovascular morbidity.
Professor Kvien initiated a collaborative project in Norway on very early arthritis, is the leader of the Norwegian NOR-DMARD registry, an observational study of prescriptions of DMARDs and biological agents in Norway and was the principal investigator of the Norwegian government funded NOR-SWITCH trial which was published in Lancet 2017. He has published more than 550 original research publications in international peer-reviewed journals, was President of the European League Against Rheumatism (EULAR) from 2005 to 2007 and was the Editor-in-Chief of the world-leading rheumatology journal for original research – Annals of the Rheumatic Diseases – from 2008 to 2017.
Professor Kvien was recognized as Master of the American College of Rheumatology in 2015, and is honorary member of the Norwegian, Finnish, and Czech rheumatological societies as well as the Norwegian Rheumatism Association. He also received the EULAR meritorious service award in 2017, the Carol Nachman medal in 2018 for his contributions to international rheumatology, and the Norwegian King recently appointed professor Kvien as Officer First Class of the Royal Order of St Olav.
Tore K. Kvien has received fees for speaking and/or consulting from AbbVie, Biogen, BMS, Celltrion, Eli Lilly, Evopharma, Hikma, MSD, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, Sanofi and UCB and received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB.
Prof. Luis Puig
Director of the Department of Dermatology, Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain
Prof. Luis Puig Sanz is Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP), and Professor of Dermatology at the Universitat Autònoma de Barcelona (UAB) Medical School, both in Barcelona, Spain.
During the past 14 years, Prof. Puig’s clinical research has focused on the treatment of psoriasis with biological agents. He is considered to be a key opinion leader in this field, both nationally and internationally, having taught at numerous national and international conferences, workshops, and seminars. He has authored several book chapters and numerous papers in indexed journals. He is a member of the Editorial Board of Dermatology and other dermatology journals.
Prof. Puig is a member of several national and international scientific societies, including AEDV, CILAD, EADV, AAD, ASDP, GRAPPA and ESDR. He is currently a member of the Board of Directors of the EADV, in representation of Spanish members (2013-9), Co-chair of the Psoriasis Task Force of the EADV, councilor of the International Psoriasis Council (2012-), President of the Scientific Board of the Psoriasis International Network (2016-) and the Fondation René Touraine (2008-), member of the European Dermatology Forum (2017-), board member of the International Psoriasis Council (2018-), and Vice President of the Administration Council of the Fondation René Touraine (2018-).
Luis Puig Sanz receives honoraria for speaking and consulting from: Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Fresenius-Kabi, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.
Prof. Puig Sanz has participated in company-sponsored speaker’s bureaus for: Celgene, Janssen, Lilly, MSD, Novartis, and Pfizer.
Grants and research support have been received from: Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB.
Prof. Hendrik Schulze-Koops
Head of the Department of Rheumatology, Munich
University Hospital, Munich, Germany
Prof. Hendrik Schulze-Koops received his doctorate of medicine from the University of Hamburg, Germany, in 1988 for his work on the arthritogenic factors of Yersinia. He was promoted to Professor of Clinical Immunology at the University of Erlangen-Nuremberg, Germany, in 2006, and since then has held the position of Professor of Internal Medicine and Rheumatology at Munich University Hospital, Germany,. With nearly 30 years' experience in the field of clinical immunology, Prof. Schulze-Koops is one of the foremost authorities in rheumatism.
Prof. Schulze-Koops' current research focuses on cellular and molecular pathogenesis of autoimmune diseases, and he is currently leading research into mechanisms of sustained autoimmune T-cell activity in diseases, such as rheumatoid arthritis with the two important aspects of increased activity of inflammatory effector T cells and decreased functionality of regulatory T cells.
Hendrik Schulze-Koops receives honoraria for lectures and advices from AbbVie, Actelion, AstraZeneca, Biogen International, Boehringer Ingelheim, BMS, Celgene, Celltrion, Chugai, Cinfa Biotech, GSK, Hospira, Janssen-Cilag, Lilly, MSD, Medac, Merck, Mundipharma, Novartis, Pfizer, Hexal Sandoz, Sanofi, Roche, UCB.
The Division of Rheumatology and Clinical Immunology at the University of Munich receives funding and support from AbbVie, AstraZeneca, Baxter, Biotest, BMS, Celgene, CSL Behring, GSK, Hospira, Janssen Cilag, MSD, Lilly, Mundipharma, Novartis, Pfizer, Octapharma, Medac, Hexal Sandoz, Roche, UCB.
This website has been developed and funded by Biogen and is intended for healthcare professionals outside of the United States.